Symposia

Session 1: Grand Opening

Cancer Care and Research in the UAE

WIN Consortium: Past, Present, Future

Opening Ceremony

Keynote Lecture
Immune Checkpoint Blockade in Cancer Therapy: New Insight into Mechanisms of anti-CTLA-4, anti-PD-1, and Combination

Session 2: Precision Genomics: From Bench to Bedside

A Visionary Odyssey Beyond Boundaries: The Evolution of Tumor-Agnostic Drug Development in Precision Medicine

Therapeutic Targeting of EMT and Tumor Plasticity

Role of Liquid Biopsy in Targeted Therapy

The Emirati Genome Program: A National Enabler of Precision Medicine

Roadmap for Precision Genomics in Routine Cancer Care in the UAE

Session 3: Precision Immunotherapy: The Next 5 Years

Integrating Clinical and Laboratory Research to Identify Mechanisms of Response and Resistance to Immune Checkpoint Therapy

Role of Liquid Biopsy in Immunotherapy

Transcriptomics at WIN: Opening the Multi-omic Era

Landscape of Immunotherapy in the UAE

Session 4: Precision Research

Landscape of Translational Cancer Clinical Trials in the UAE

Oral Abstracts and Awards

Session 5: Molecular Tumor Board

Interactive Session with Cases from the UAE

Session 6: Radiation Oncology in Precision Medicine

A Genomic Adjusted Radiation Dosing Paradigm to Biologically Personalize Radiation Therapy

Radiotherapy as Immunotherapy for Cancer

Session 7: Precision Communityomics

Diversity and Equity in Precision Oncology

Tools for Precision Communityomics

Session 8: Precision Diagnostics

Panel Discussion

WIN 2022 Program

Welcome & Opening Remarks

Lifestyle-based Prevention Strategies

Rewriting the Code of Life: CRISPR-Cas Genome editing

Innovation in Clinical Trials: WINTHER trial

Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials

Innovation in Clinical Trials: SPRING_01 Proof of Concept Trial exploring Combination of Three Targeted Drugs

Systems Immunology in IO: A view from the Parker Institute

Innovative Ways of Assessing Durable Response to Immunotherapy

Direct Targeting of STAT3 Alone and in Combination with Immune Checkpoint Inhibitors to Treat Solid Tumors

CDK4/6 Inhibitors in Breast Cancer; today's real and future dream

The Value of Personalized Medicines for Healthcare Systems in Europe - Considering enablers to the adoption of personalized medicines in Europe

Development and Application of Precision Oncology in China

National Cancer Grid of India - Earthshots over Moonshots

Innovative Algorithms and IT Platform to Support Clinical Trials

Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations

Oncobox, RNA Sequencing and Molecular Pathway Analysis-Based Second Opinion System for Prescription of Target Drugs to Advanced Cancer Patients: Concept, Design and Results of Clinical Trials

Matched Tumor/Normal Expression Profiling from Small FFPE Samples

Celebrating 10 years of the WIN Symposium

Final Program of WIN Symposium 2018

The TAPUR Family of Clinical Trials: Building a Global Data Sharing Platform in Precision Oncology

NCI's Integrated Precision Oncology Networks

The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC

How Robust Are Your Archives?

Patients Driving Progress

MyPathway Study: A Novel Precision Oncology Multiple Basket Trial

Precision CAR T cells Therapeutics

Precision Oncology Approaches for Immunotherapy

Early development in oncology: Are the MTD and monotherapy efficiacy still the best objectives?

Implementing Precision Medicine in Oncology: The IMPACT Clinical Trials at MD Anderson Cancer Center

The 'Greatest Hits' of Precision Oncology: the view from the newsroon

Patients' access to Precision Oncology

Dynamic monitoring HER2 amplification of circulating DNA in metastatic colorectal cancer patients treated with cetuximab

Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Welcome

No innovation about us without us

Patient perspectives

Keynote Lecture: A systems biology approach to elucidating and targeting functional tumor dependencies from patient-derived RNASeq profiles

Affordable next-generation sequencing to support therapeutic decision-making

Monitoring the cancer genome in plasma using circulating tumor DNA

Serum miRNAs as diagnostic and prognostic tools in GI malignancies

Harnessing the biology of exosomes for diagnosis and treatment of cancer

Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mCRC

Keynote Lecture: Paths to the Curative Treatment of Cancer, ABL001: A Future Case Study?

Combination trial designs: How do we get efficiently to the most effective and tolerable combination regimen?

Towards Using Epigenetic Therapy to Improve Cancer Immunotherapy

Pro Presentation

Con Presentation

Keynote Lecture: Scientific wellness and cancer

Preclinical strategies for precision medicine in colorectal cancer: Challenges and opportunities

Cancer organoids: Limiting the need for animal models?

New challenges in drug development

Results of MINDACT clinical trial

Expediting precision cancer medicine

Keynote Lecture: The impact of next generation sequencing on the outcomes of patients with lung cancer

CRC subtypes: from molecular signatures to therapeutic opportunities

Personalizing breast cancer therapy

Pro presentation/Con presentation

Opening Addresses

The Era of Precision Cancer Medicine: A worldwide effort and challenge - Introduction to WIN Consortium

Targeting immune mechanisms

Natural killer immunity and cancer immunome

What T-cells see on human cancer

A systems biology approach to precision cancer medicine

Personalized combinatorial approaches to closing down all the key oncogenic drivers

Battle-2 Trial: Mutational landscape and clinical outcome

Drug target activation mapping through a proteomic CLIA assay: A companion diagnostic engine for personalized medicine trials

Round table of pharma and academic experts

WINTHER trial: Interim results and lessons learnt

WINTHER trial: An SME driven EUFP7 program to create an industry standard tool to optimize therapeutic decision making

SIMS - Simplified INterventional Mapping System for the identification of druggable activated pathways

SPRING - Rolling tri-therapy combinations of targeted drugs in second line of metastatic NSCLC

SUMMER - Elimination of relapse through innovative adjuvant targeted therapeutics in stage II and III NSCLC

BOOSTER - An integrative program for the discovery & validation of new blood biomarkers for NSCLC for use in early diagnosis (stage I)

Oral presentation of awarded posters

A perspective on NCI strategy and trials

ASCO's initiatives in personalized medicine

Meta analyses of 50,000 patients in personalized cancer trials

New avenues for the development and evaluation of therapy

Bottleneck problems in mutation-driven drug development and immunotherapy

Combinating radiation and immunotherapy

Intrinsic subtypes of colon cancer and their response to systemic therapy

What is new in melanoma?

Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast

The EMA adaptive pathways approach to improve timely access for patients to new medicines

End points and assessment of therapeutic efficacy in personalized cancer care

Importance of methodology certification and accreditations to perform assays

Use of targeted therapies and challenges for health payers

Challenges for foundations and cancer research organizations

WIN2015 - Open Forum & Closing Remarks

Welcome Address

WIN Consortium: Goals and strategy

Another great journey: WIN in 21st century

Molecular analysis of immune cells and immunotherapy

Reinstating immunosurveillance: A prime goal of anticancer therapies and a strategic element for combination treatments

Molecular investigations of immune cells and tumor environment: The Ovarian Cancer Model

Combining immunological and targeted agents: The way forward

Tumor-infiltrating immune cells as classifiers and predictors of outcome

What can we learn from hemato-oncology?

Molecular pathways in the treatment of leukemia

Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies

Combining interferon with targeted therapeutics to eliminate leukemia propagating cells in myeloproliferative neoplasms

Combination therapies in hematologic diseases

Systems medicine approach to optimize drugs and drug combinations for individual AML patients

General Discussion, Session 2

Innovative therapeutic initiatives and models of cooperation

Perspectives for effective cancer drug development: The EORTC SPECTA initiative

Clinical trial designs for incorporating multiple biomarkers in combination studies with targeted agents

General Discussion, Session 3

POSTER AWARDING CEREMONY AND PRESENTATION OF AWARDED POSTERS

Introduction Poster Award

Oral presentation Summary Poster P4.01: Somatic mutation analysis in clinical tumour samples to select patients for experimental therapies

Oral presentation Summary Poster P5.06: Targeted delivery of a microRNA mimic as a novel approach to therapy for malignant pleural mesothelioma

Personalized cancer therapy: Successes and challenges

Combinations of targeted therapies (part 1)

Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies

Genomic complexity of metastatic disease and the conundrum of combinations

Biology driven combination therapies: How to turn up the HEAT on cancer – A PhRMA perspective

Combinations of targeted therapies in oncology – An industry view

General Discussion, session 4

Combinations of targeted therapies (part 2)

The challenges of combinations of targeted agents in oncology

Impact of the BATTLE trial

Combining radiotherapy with immunotherapy in metastatic cancer

Growing tissue stem cells into organoids and tumeroids: Predictive assay development

New findings on fundamental mechanisms in pediatric cancers

Novel drug targets and potential combinations in childhood brain tumors

Pediatric high grade brain tumors: Epigenetic addiction of the developing brain?

Cancer Stem Cells and Malignant Progression

Blood and fluids – non-invasive investigations in oncology

Proactive P4 medicine-making blood a window into health and disease: A tipping point that is transforming healthcare

Circulating tumor cells (CTCs) or circulating DNA (cfDNA): What are the perspectives?

Personalized cancer medicine using the human protein atlas and affibodies

Wrap-up and conclusions